Document Detail

Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study.
MedLine Citation:
PMID:  16475496     Owner:  NLM     Status:  MEDLINE    
Previous investigations have reported the efficacy of tazarotene 0.1% cream for the treatment of dyschromia associated with photoaging and for acne vulgaris. The present investigation assessed tazarotene 0.1% cream for the treatment of postinflammatory hyperpigmentation (PIH) in a double-blind, randomized, vehicle-controlled study of 74 patients from darker racial ethnic groups who had acne. Once-daily application of tazarotene cream was shown to be effective against PIH, achieving significantly greater reductions compared with vehicle in overall disease severity and in the intensity and area of hyperpigmentation within 18 weeks (P< or =.05). Mean levels of erythema, burning, and peeling were no more than trace in both groups throughout the study, and mean levels of dryness were no more than mild in both groups. In our study, tazarotene cream was effective and well tolerated in the treatment of PIH in patients with darker skin.
Pearl Grimes; Valerie Callender
Related Documents :
6205676 - The treatment of resistant warts with intralesional bleomycin: a controlled clinical tr...
19874376 - Topical tazarotene vs. coal tar in stable plaque psoriasis.
17668526 - Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin ...
14510996 - Treatment of darier's disease with photodynamic therapy.
7943936 - Catheter-directed urokinase thrombolysis: an adjunct to pta/surgery for management of l...
1458946 - Evaluation of the consistency of acute physiology and chronic health evaluation (apache...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cutis     Volume:  77     ISSN:  0011-4162     ISO Abbreviation:  Cutis     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-02-14     Completed Date:  2006-05-25     Revised Date:  2013-09-12    
Medline Journal Info:
Nlm Unique ID:  0006440     Medline TA:  Cutis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  45-50     Citation Subset:  IM    
Vitiligo and Pigmentation Institute of Southern California, Los Angeles, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acne Vulgaris / complications,  drug therapy*
Administration, Cutaneous
Aged, 80 and over
Dermatologic Agents / adverse effects,  therapeutic use*
Double-Blind Method
Hyperpigmentation / drug therapy*,  etiology
Middle Aged
Nicotinic Acids / adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Dermatologic Agents; 0/Nicotinic Acids; 118292-40-3/tazarotene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blastic natural killer-cell lymphoma: a case report.
Next Document:  Post-translational modification(s) and cell distribution of Streptomyces aureofaciens translation el...